PHILADELPHIA — Four “pay-for-delay” agreements that Cephalon Inc. entered into with separate generic drug manufacturers eight years ago don’t establish a conspiracy among the companies, a federal judge has ruled.

In the agreements, Cephalon paid a “substantial amount of money” to the generic companies, U.S. District Judge Mitchell Goldberg said, and the companies agreed to enter the market for a lucrative narcolepsy drug in April 2012. The agreements were made in late 2005 and early 2006.